



Gaining momentum.

**Annual General Meeting
November 2021**

DISCLAIMER AND SAFE HARBOR



Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (“Prescient” or the “Company”), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’, ‘expect’, ‘plan’, ‘believe’, ‘guidance’, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management’s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.


This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

The contents of this document are confidential information of Prescient. These contents are made available on a ‘for your eyes only’ basis to the person to whom it was sent by Prescient. The purpose of the disclosure is to facilitate commercial and confidential discussions between the discloser and Prescient. It should not be forwarded without without the prior written consent of the Company.

At the 2020 AGM we said:



Innovative Pipeline in Personalised Medicine



Key achievements during another productive year

Cell Therapies

- Strategic review of OmniCAR to identify three highly differentiated internal programs
 - AML
 - Her2+ solid tumours
 - GBM
- Initiation and progress of these OmniCAR programs
- Manufacturing and testing of key OmniCAR components
- Successful demonstration of unique OmniCAR features
- CAR-T agreement with Peter Mac
- Transitioned Cell Therapy Enhancement program to Peter Mac

Targeted Therapies

- Progression of PTX-200 in AML
- Completion of PTX-100 Phase 1b basket trial
 - Excellent safety profile
 - Encouraging data in area of unmet need
- Manufacturing PTX-100
- Investigating IST opportunities

Operations

- **Building world class capabilities**
- Bolstering PTX team in areas including:
 - cell therapy
 - immunology
 - biologic engineering
 - clinical operations
- PTX & Peter Mac: a very productive and cohesive relationship
- Full time post docs at Peter Mac together with Professor Phil Darcy
- Significant business development interest



Rebecca Lim, PhD
Director of Scientific Affairs




Daniel A. Shelly, PhD, MBA
VP – Business Development &
Alliances



Leanne West
Director of Clinical Affairs and
Operations

Assembling a world class Scientific Advisory Board



Professor Phil Darcy

Eminent CAR-T expert



Professor H. Miles Prince, AM

Internationally renowned
haematologist



Professor Don O'Rourke, MD

Neurosurgeon & brain cancer
key opinion leader

Achievements becoming reflected in company valuation

- PTX one the best performing biotech stocks on ASX this year
- Significantly improved liquidity



Overcoming challenges

COVID-19



- No specific and material disruptions, but impossible to escape its impact
- US disruptions in 2021
 - AML recruitment
 - Manufacturing and logistics bottlenecks
 - Assay development
- Things back on track
- Pre-clinical work forged ahead despite Australian lockdowns

Science and technical



- New modality required bolstering in-house expertise in new areas
- Matched by world-class SAB and Peter Mac collaboration
- Would novel experiments work in our hands? Even then, how long would it take?
- Outcomes: successful and rapid progress across programs

Building OmniCAR awareness



- One challenge of being “ahead of the curve” is educating stakeholders on cell therapy limitations and OmniCAR’s capabilities
- Industry, clinicians, investors
- The more parties understand cell therapy, the more they appreciate the value of the platform!
- Playing the long game, and it is starting to pay off.

PTX-100

FIRST IN CLASS
RAS PATHWAY INHIBITOR

PTX-100 PHASE 1B BASKET STUDY COMPLETED



- Phase 1b PK/PD safety study
- Focus on cancers prone to Ras and Rho mutations
- Basket trial of:
 - Gastric cancer
 - Pancreatic cancer
 - Colorectal cancer
 - Myeloma
 - T-cell lymphomas



Professor H. Miles Prince, AM
Principal Investigator



Prescient takes its PTX-100 trial to next level after Phase 1b success

July 28, 2021 02:50 PM AEST

Excellent safety profile

- PTX-100 well tolerated up to and including 2,000 mg/m²
- No SAEs related to PTX-100



SAE: SERIOUS ADVERSE EVENT
PR: PARTIAL RESPONSE (REDUCTION OF DISEASE)
PFS: PROGRESSION FREE SURVIVAL (TIME UNTIL DISEASE WORSENS)
SOC: STANDARD OF CARE

Prescient Therapeutics (ASX:PTX) expands trial of PTX-100

Health Care

Early clinical activity

- PRs in 2 patients with aggressive refractory TCL
- **Expected PFS of <4 months on SoC**
 - r/r CTCL: **12 months** (19 cycles)
 - r/r PTCL: **17 months so far** (24 cycles, still on therapy)

TCL: T CELL LYMPHOMA
CTCL: CUTANEOUS T CELL LYMPHOMA
PTCL: PERIPHERAL T CELL LYMPHOMA

- 8 – 12 patients with r/r T cell lymphoma (esp PTCL)
- Potential bridge to registration study
- Focussing on sweet spot in an area of considerable unmet need
- Shortest path to market
- Awaiting delivery of drug product to Australia – US-wide manufacturing and logistics bottlenecks!
 - Working closely with manufacturer

Case Study

- pralatrexate (Foloty[®])
- Approved for PTCL
 - 5,600 cases/year in US
- US\$450,540 per patient, per year

FOLOTYN
(pralatrexate injection) 




PTX-200

NOVEL AKT INHIBITION

PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA

- Building upon encouraging Phase 1 results with PTX-200 (monotherapy)
- PI Professor Jeff Lancet at Moffitt, with Dr Tara Lin at KUMC
- 18 patients with cytarabine held constant at 200-400 mg/m² as continuous infusion
 - 3 CRs so far
- Both sites were impacted by general COVID-19 disruptions in 2021, which impacted recruitment and correlative analysis
- Currently screening second cohort at 45 mg/m²
- Granted Orphan Drug Designation by US FDA



Jeffrey E Lancet, M.D.
Principal Investigator







OmniCAR

Universal, Next Generation CAR-T

How does the CAR-T process work?



OmniCAR: flexible, modular CAR platform



Associate Professor
Daniel J. Powell, Jr




Professor
Andrew Tsourkas



T-cell



Thorough strategic review yielded 3 internal OmniCAR programs




- Prescient understands the landscape, challenges and opportunities

**What is the broader
vision for cell therapy?**

The future is efficient yet personalized: OmniCAR cells + “plug & play” binder library

Step 4:
**Tailored, optimised
& safe:**
OmniCAR- induced
tumor killing with
post-infusion control




Step 3:
Pair binders with OmniCAR cells
(T cells; NK; auto/allo)

Step 2:
Match patient's antigens
to corresponding
binders

Step 1:
Patient sample analysed to
determine antigen profile

Strategically positioned in a rapidly moving landscape for cell therapy



Current

In development

With OmniCAR, this is just the start for CAR-T



- Seeking to enhance **current generation CAR-Ts**....
- ...& more significantly, **help realise the broader potential of CAR-T**, which is much bigger opportunity!

Current generation CAR-T

- Autologous T cells
- B-cell malignancies

Cell types

- Allogeneic (off the shelf) T-cells
- iPSC derived cells
- NK cells

A whole new toolbox of Binders

- Re-purposing antibodies into next-gen CARs will **accelerate the whole field**
- Non-CAR-T companies can leapfrog into next-gen CAR-T

Overcoming T-cell Exhaustion

Companion diagnostics

Addressing escape & relapse

Adaptable and tailored CARs

Other hematological malignancies

Solid tumours!!!

- Novel antigens & optimising antigen combinations
- Overcoming trafficking
- Tumor microenvironment

Safer CAR-T = more applications

- Safer and more controllable next-gen therapies will bring CAR-T to many more patients
- Opens opportunities beyond oncology

Business development

- Extremely active business development activities, spearheaded by Dr Dan Shelly (US)
- Different parties have different drivers
 - **Incumbent cell therapy players:** Top priorities are maximizing returns on their existing programs
 - **Emerging companies:** Believe the “second mouse will get the cheese”; looking for technologies to leapfrog competitors
 - **Companies with binders:** e.g. antibody companies. See OmniCAR as a way to add enter the cell Tx field and bolster their pipelines
- OmniCAR can benefit all these groups!
- Prescient is playing the long game for the right parties

Considerations include:



What is the party bringing to the table, and how will it help us win?



Balance between doing a deal and not jeopardising the bigger picture

Summary

Key building blocks to PTX Future Value

1

OmniCAR

- Next generation universal CAR platform
- AML
- Her2+ solid tumours
- GBM
- 3rd party opportunities

2

Cell Therapy Enhancements


- Enhancing current generation CAR-T
- Also applicable to next gen
- Collaboration with Peter Mac
- 100% ownership of Intellectual Property

3

Targeted therapies

- PTX-100
- PTX-200

In the next 12 months we will work towards:





Thank you!

ASX code: PTX

www.ptxtherapeutics.com

Appendices

Key Challenges confronting the field of CAR-T



Time and Cost
of delivering treatment



Targets

Finding targets that work;
Antigen heterogeneity - esp. in solid tumours



Safety

CAR-T can have serious
safety concerns



Exhaustion

Persistent stimulation of CAR-Immune
cells leads to exhaustion



No Control

Clinicians have no control
of cells post infusion



Escape


Antigen loss leads to relapse

OmniCAR can do what conventional CAR-T cannot

Conventional CAR-T



- Soldier with only one map
- Single weapon
- Only trained to hit one target
- Incapable of redirection
- No communication or control in the field





OmniCAR


CD33 & CLL-1 for AML

Global AML market opportunity



- AML market is expected to reach **US\$5.1B in 2029**
- CAGR of 13.6%
- Growth assumptions largely based on new targeted therapies
- **Any CAR-T breakthrough in AML would grow this market further**

Landscape for CAR-T in blood cancers



For CAR-T to succeed in AML, it must overcome:



Safety

AML patients are especially ill with many unable to tolerate vigorous therapies like CAR-T



Rapidly Mutating Disease

AML can mutate mid-therapy, quickly rendering single CAR-Ts ineffective



Rapid Disease Progression


Even if multiple current generation CAR-T therapies were available, resistant patients are likely to progress before subsequent therapies are manufactured for them

OmniCAR is uniquely placed to address these CAR-T challenges in AML


Targets	OmniCAR features	Comments
CD33 + CLL-1	<ul style="list-style-type: none">• Titration (and ability to switch off/on) for improved safety & tolerability• Co-arming against CD33 & CLL-1• Sequential or simultaneous targeting• Ability to cease treatment to avoid neutropenia	<ul style="list-style-type: none">• Validated targets• Expressed on >90% of AML blasts & LSCs• Only 1 of 3 programs worldwide targeting CD33 & CLL1

Unique OmniCAR flexibility important in AML

Sequentially



Simultaneously



AML peer with CD33/CLL1 CAR-T

	Legend Biotech Corp	Prescient Therapeutics
Ticker	NASDAQ: LEGN	ASX: PTX
Market Cap	A\$8.2B	A\$174M
AML program	CD33 + CLL1	OmniCAR CD33 + CLL1
Generation	Current generation, autologous	Next generation, autologous
Stage of development	Phase 1	Discovery/Pre-clinical
Titratable for safety	✗	✓
Switch on/off	✗	✓
Persistent dosing without new cell product	✗	✓
Able to switch antigen targeting	✗	✓



OmniCAR

Her2 for Ovarian, Breast & Gastric cancers

Key challenges for CAR-T in solid tumours



Targets

Limited targets that are cancer-specific
Leads to on-target, off-tumour effects



Safety

Ability to titrate doses safely and switch off in the event of adverse events



Trafficking

Inability of T-cells to reach tumour sites and penetrate physical barriers



TME

Overcoming an immunosuppressive Tumour Microenvironment once they get there

OmniCAR's features enable it to address these solid tumour challenges

Huge market opportunities for Her2+ cancers


New Her2+ cases/year	
Ovarian Cancer	87,000
Breast Cancer	340,000
Gastric Cancer	209,440

- Very large patient populations
- “Basket study” approach
- Patients failing Herceptin treatment would make excellent candidates


1. World Cancer Research Fund
2. Shang AQ, et al. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. *Cancer biology & therapy*. 2017;1–9
3. Luo, H et al, The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. *PLoS ONE* 13(1) 2018
4. Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-97.

Target	OmniCAR features	Comments
Her2	<ul style="list-style-type: none">• Titration for improved safety & tolerability• Persistent binder dosing for improved efficacy and persistence• TME and checkpoint enhancements	<ul style="list-style-type: none">• Validated target• Large difference of antigen expression on tumor vs healthy tissue• Most mature next-gen Her2 CAR-T program

OmniCAR Her2: durable, dose-dependent CAR-T activity



- Ovarian cancer model, using anti-Her2 OmniCAR
- Loading more binder results in **proportionate killing** of cancer...
- ...and **proportionate survival**
- **Lasting effects** even when cease dosing of binder



Notable Her2 CAR-T peers



- Prescient the **most advanced next-generation CAR-T** program in Her2

	Shenzhen Geno-Immune Medical Institute ¹	Tessa Therapeutics ²	Fate Therapeutics	Novartis ³	Calibr	Xyphos	Prescient Therapeutics
Status	Hospital	Private Company	NASDAQ: FATE; Market cap A\$9.3B	Global pharma company	Research Institute	Acquired by Astellas 2019	ASX: PTX Market cap A\$174M
Indications	Breast cancer	Multiple cancers	Breast & other unspecified cancers	Ovarian cancer	Breast cancer	Solid cancers (unspecified)	Ovarian, Breast, Gastric
Generation	Current generation, autologous	Current generation + oncolytic virus	Current generation, autologous	Current generation, autologous	Next generation, autologous	Next generation, autologous	Next generation, autologous
Stage of development	Phase 2	Phase 1	Discovery	Discovery	Discovery	Discovery	Pre-clinical



OmniCAR

Her2 & EGFRviii for GBM


CAR-T challenges in GBM: single antigen targeting

- Limited effectiveness of CAR-Ts only targeting a single antigen in GBM

“A major limitation of a single-antigen targeting in GBM is the inherent heterogeneity and plasticity of the tumor cells, allowing some cells to escape CAR-T cell killing due to the loss of the targeted antigen...”


“...single antigen-targeting CAR-T cells fail to completely eradicate brain tumors resulting in antigen negative relapses”

- By contrast, CAR-Ts targeting multiple antigens have demonstrated anti tumor responses and more importantly prevented antigen escape *in vivo*



Competitive landscape in CAR-T GBM

Stage	# CAR-T programs
Discovery/Pre-clinical	25
Clinical	16
TOTAL	41



OmniCAR 1 of only 3 targeting multiple antigens

- OmniCAR the only next gen CAR-T
- (The 2 other programs are at a not-for profit)

Targets	OmniCAR features	Comments
Her2 + EGFRviii	<ul style="list-style-type: none">• Multivalent antigen targeting• Persistent binder dosing for improved efficacy & persistence• Titration for improved safety	<ul style="list-style-type: none">• 1 of 3 multiple antigen programs in the world• Single antigen targeting is inadequate in GBM